Literature DB >> 24995716

Sublingual buprenorphine as an analgesic in chronic pain: a systematic review.

Joyce Cote1, Lori Montgomery.   

Abstract

OBJECTIVE: There is growing interest in the use of sublingual buprenorphine for the treatment of chronic pain due to the unique pharmacology of buprenorphine, widespread use of the transdermal buprenorphine patch for chronic pain, and recent availability of sublingual buprenorphine tablets for the treatment of opioid dependence. The aim of this systematic review was to evaluate the evidence from clinical trials that have assessed the effectiveness of sublingual buprenorphine for chronic pain analgesia.
METHODS: Electronic searches of MEDLINE, Embase, CINAHL, Web of Science, and the Cochrane Database of Systematic Reviews were used to identify clinical trials of sublingual buprenorphine for the treatment of chronic pain.
RESULTS: Ten trials involving 1,190 patients were included in the review. Due to heterogeneity of studies, pooling of the results and meta-analysis were not possible. All studies reported that sublingual buprenorphine demonstrated some effectiveness as a chronic pain analgesic. The majority of studies were observational and of low quality.
CONCLUSIONS: Preliminary trials suggest a plausible role; however, due to a paucity of high-quality trials, the current evidence is insufficient to determine the effectiveness of sublingual buprenorphine for the treatment of chronic pain. Rigorous further trials are warranted. Wiley Periodicals, Inc.

Entities:  

Keywords:  Buprenorphine; Chronic Pain; Systematic Reviews

Mesh:

Substances:

Year:  2014        PMID: 24995716     DOI: 10.1111/pme.12386

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  9 in total

Review 1.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 2.  Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids.

Authors:  Suhani Dalal; Ahish Chitneni; Amnon A Berger; Vwaire Orhurhu; Bilal Dar; Bennett Kramer; Anvinh Nguyen; John Pruit; Charles Halsted; Alan D Kaye; Jamal Hasoon
Journal:  Health Psychol Res       Date:  2021-08-06

3.  Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.

Authors:  Matthew J Worley; Keith G Heinzerling; Steven Shoptaw; Walter Ling
Journal:  Exp Clin Psychopharmacol       Date:  2015-08-24       Impact factor: 3.157

4.  Patient outcomes after opioid dose reduction among patients with chronic opioid therapy.

Authors:  Sara E Hallvik; Sanae El Ibrahimi; Kirbee Johnston; Jonah Geddes; Gillian Leichtling; P Todd Korthuis; Daniel M Hartung
Journal:  Pain       Date:  2022-01-01       Impact factor: 7.926

5.  Random Forest Segregation of Drug Responses May Define Regions of Biological Significance.

Authors:  Qasim Bukhari; David Borsook; Markus Rudin; Lino Becerra
Journal:  Front Comput Neurosci       Date:  2016-03-09       Impact factor: 2.380

6.  Buprenorphine Alters Inflammatory and Oxidative Stress Molecular Markers in Arthritis.

Authors:  Mahadevappa Hemshekhar; Vidyanand Anaparti; Carol Hitchon; Neeloffer Mookherjee
Journal:  Mediators Inflamm       Date:  2017-05-09       Impact factor: 4.711

7.  Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: A case report.

Authors:  Raman Sandhu; Rebecca Zivanovic; Sukhpreet Klaire; Mohammadali Nikoo; Jennifer Rozylo; Pouya Azar
Journal:  Can J Pain       Date:  2019-04-25

Review 8.  Benefit-Risk Analysis of Buprenorphine for Pain Management.

Authors:  Martin Hale; Mark Garofoli; Robert B Raffa
Journal:  J Pain Res       Date:  2021-05-24       Impact factor: 3.133

9.  Sublingual Buprenorphine: A Feasible Alternative for Treating Breakthrough Chronic Pain.

Authors:  Abhijit S Nair; Srinivasa Shyam Prasad Mantha; Kodisharapu Praveen Kumar; Basanth Kumar Rayani
Journal:  Indian J Palliat Care       Date:  2019 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.